Biologic therapy in esophageal and gastric malignancies: Current therapies and future directions

Keyphrases

• Biologic Therapy 100%
• Biological Agents 33%
• C-Met 33%
• Current Therapies 100%
• Epidermal Growth Factor Receptor 33%
• Esophageal Malignancy 100%
• Esophagogastric Adenocarcinoma 33%
• Gastric Adenocarcinoma 33%
• Gastric Malignancy 100%
• Human Epidermal Growth Factor Receptor 2 (HER2) 66%
• Human Malignancies 33%
• Immunomodulator 33%
• Locally Advanced 33%
• Mammalian Target of Rapamycin (mTOR) 33%
• Metastatic Disease 33%
• National Comprehensive Cancer Network 33%
• Overexpression 33%
• Phase II Clinical Trial 33%
• Phase III Clinical Trial 33%
• Ramucirumab 33%
• Second-line Therapy 33%
• Targeted Immunomodulator 33%
• Targeting Antibodies 33%
• Trastuzumab 33%
• Vascular Endothelial Growth factor-C (VEGF-C) 33%
• VEGFR-2 Inhibitors 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Biological Product 100%
• Clinical Trial 50%
• Epidermal Growth Factor Receptor 50%
• Epidermal Growth Factor Receptor 2 100%
• Gamma Urogastrone 100%
• Immunomodulating Agent 100%
• Malignant Neoplasm 50%
• Mammalian Target of Rapamycin 50%
• Metastasis 50%
• Ramucirumab 50%
• Stomach Adenocarcinoma 50%
• Trastuzumab 50%
• Vasculotropin 50%
• Vasculotropin Receptor 2 50%

Medicine and Dentistry

• Biological Product 25%
• Biological Therapy 100%
• Cancer 100%
• Clinical Trial 25%
• Epidermal Growth Factor Receptor 25%
• Epidermal Growth Factor Receptor 2 50%
• Gamma Urogastrone 50%
• Immunomodulating Agent 50%
• Malignant Neoplasm 25%
• Mechanistic Target of Rapamycin 25%
• Metastatic Carcinoma 25%
• Ramucirumab 25%
• Stomach Adenocarcinoma 25%
• Trastuzumab 25%
• Vasculotropin 25%
• Vasculotropin Receptor 2 25%